Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New program helps dementia patients ditch unneeded pills

NCT ID NCT06335953

Knowledge-focused Sponsor: Johns Hopkins University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 2 times

Summary

This study tested whether a pharmacist-led program could help older adults with dementia and their caregivers reduce unnecessary medications. The program included an educational brochure, a telehealth visit with a pharmacist, and tailored recommendations for the patient's doctor. 360 participants were enrolled to see if at least one medication could be safely stopped within 3 months.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

474 people

The number who actually took part.

Started

May 2024

Finished

Oct 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

65 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥65 years * Diagnosis of dementia from International Classification of Diseases (ICD-10) visit codes or from the EHR problem list * Five or more medications * Only active patients, defined as having \>1 visit to the primary care clinic within the past year will be included Care partners: * Family or other companions \>21 years old who regularly help the patient manage medications. Exclusion Criteria: * As the pragmatic trial will be based on primary care, individuals residing in long-term care facilities or enrolled in hospice will be excluded. * Participants must hear well enough to communicate by telephone in English.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alzheimer's disease and related dementias are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Alzheimer disease Cognitive Dysfunction dementia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Alzheimer's disease and related dementias Mild cognitive impairment Polypharmacy

Contacts and locations

Locations

  • Johns Hopkins Community Physicians

    Baltimore, Maryland, 21209, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.